Dear Sir, Recently, Cominacini et al. [1] described increased concentrations of soluble adhesion molecules in patients suffering from insulin-dependent and non-insulin-dependent diabetes mellitus (NIDDM). Soluble E-selectin and intercellular adhesion molecule-1 (ICAM-1) concentrations were increased in NIDDM whereas vascular adhesion molecule-1 (VCAM-1) demonstrated no significant changes when compared to a control group. Interestingly, E-selectin concentrations positively correlated with glycaemic control as measured by glycated haemoglobin values.
We agree that increased levels of E-selectin reflect endothelial cell activation. However, it should be mentioned that by using E-selectin alone it seems impossible to characterise the true status of the vascular endothelium in disease. A set of parameters including von Willebrand factor, soluble thrombomodulin and endothelial cell-specific soluble adhesion molecules [3] represent an appropriate tool with which to prospectively investigate vascular endothelium in diabetes and its complications. Unfortunately, to the best of our knowledge, no such study has been performed.
Finally, it is tempting to speculate on the pathophysiological significance of increased soluble adhesion molecules in the complex network of humoral and cellular factors resulting in vascular diabetic complications. Soluble endothelial adhesion molecules (E-selectin, VCAM-1) have recently been shown to mediate angiogenesis [4] . Moreover, this effect seems to be independent of the release of angiogenic cytokines by the endothelium. Vascular diabetic complications depend on neovascularisation, and angiogenic factors including vascular endothelial growth factor [5] and insulin-like growth factors I and II [6, 7] have been associated with the progression of diabetic retinopathy. Hence, at least two of the soluble adhesion molecules are to be added to a growing list of molecules promoting angiogenesis in a variety of diseases including diabetes [8] . Future studies on soluble adhesion molecules are required to provide answers to many unresolved questions. One of the most intriguing concerns the proposed pathogenic role of increased soluble adhesion molecules and whether they simply reflect endothelial cell activation/injury in diabetes. If the former hypothesis proves correct, soluble adhesion molecules such as E-selectin and VCAM-1 might become target molecules with which to fight vascular diabetic complications by using antiangiogenic treatment approaches. Response from the authors Dear Sir, Dr. Steiner et al. discuss our recently published results on adhesion molecules in diabetic patients [1] . In this paper increased E-selectin concentrations were found in patients with insulin-dependent and non-insulin-dependent diabetes mellitus (NIDDM) and in a group of dystipidaemic subjects. Intercellular adhesion molecule-1 (ICAM-1) levels were found to be elevated only in the patients with NIDDM while no differences in vascular adhesion molecule-1 (VCAM-1) concentrations were detected in the other groups of subjects. Plasma Eselectin positively correlated with the glycated haemoglobin in the diabetic patients. E-selectin, however, was not related to the concentration of plasma lipids despite the fact that it was found to be elevated in hyperlipoproteinaemic subjects. In a previous paper Steiner et al. [2] performed a similar study in 60 patients suffering from NIDDM in order to examine soluble adhesion molecules and their association with metabolic control and cardiovascular risk factors. When compared to control subjects, elevated levels of E-selectin and VCAM-1 levels were found whereas the ICAM-1 concentration was similar. In Steiner's investigation the levels of adhesion molecules were not correlated with glycaemic control. At variance, E-selectin showed a significant correlation to LDL cholesterol.
I agree with the fact that consideration of Steiner's report [2] could have positively influenced the discussion provided in our paper. Unfortunately our investigation was planned, written and sent for publication before we could have this report to hand. Steiner's report therefore was not deliberately omitted and we were perfectly aware that other data on adhesion molecules in diabetic patients had been published previously [3, 4] .
There are differences in the results of the two papers, but their main result, i. e. the increase of E-selectin in patients suffering from NIDDM is similar. I believe that this finding is extremely important.
Contrary to Steiner's investigation, we did not find a significant correlation between E-selectin and lipid levels and LDL cholesterol in particular. Actually, in order to exclude possible interference from plasma lipids on the plasma concentrations of E-selectin and other adhesion molecules, only the patients with lipid parameters similar to those of the control group were considered in our study. In Steiner's investigation both LDL cholesterol and triglyceride levels were significantly
Corresponding author: Dr. L. Cominacini, Istituto di Semeiotica e Nefrologia Medica, Universit& di Verona, Ospedale Policlinico, 1-37134 Verona, Italy higher in the diabetic than in the control group. Given the demonstrated association between increased lipid concentrations and E-selectin in dyslipidaemic patients [1] the weak association between E-selectin and LDL cholesterol concentrations found by Steiner and co-workers [2] may also reflect the augmented concentration of the lipoprotein in the diabetic patients relative to the control subjects. The fact that in our study we did not find a relationship between E-selectin and LDL cholesterol concentrations in the group of dyslipidaemic patients may also be due to the limited number of subjects studied.
Contrary to our results [1] , in Steiner's investigation the levels of soluble adhesion molecules failed to correlate with glycaemic control [2] . On the basis of the already published results, of course, it is difficult to explain why we found a correlation between E-selectin concentrations and glycaemic control and Steiner and co-workers did not. It should be noted, however, that the diabetic patients studied in Steiner's investigation were not only dyslipidaemic, but 70 % were also hypertensive and it has recently been demonstrated that hypertension is a pathological condition also characterized by increased levels of plasma E-selectin [5] . In these patients, therefore, there were at least two other risk factors in addition to diabetes per se that could interfere with the expression of E-selectin on endothelial cells and hence on its plasma concentration.
We believe that the only correct way to accurately demonstrate a possible relation between plasma E-selectin concentrations and glycaemic control is to study these parameters in the same patient before and after good glycaemic control has been achieved. It must be pointed out, however, that early glycation products, for example glycated haemoglobin, are poor indicators of irreversible advanced glycation end product formation and that only these products can induce the expression of adhesion molecules, especially E-selectin [6] . Future studies on the correlation between adhesion molecule plasma concentrations and circulating advanced glycation end products in diabetic patients are required.
Yours sincerely L. Cominacini, A. Fratta Pasini, U. Garbin, V. Lo Cascio
